Altimmune ALT

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.01 (+0.18%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Altimmune (ALT)
    Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $5.57

    • Market Cap

      $428.97 Million

    • Price-Earnings Ratio

      -17.41

    • Total Outstanding Shares

      77.01 Million Shares

    • Total Employees

      59

    • Dividend

      No dividend

    • IPO Date

      October 6, 2005

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      910 clopper road, Gaithersburg, MD, 20878

    • Homepage

      https://www.altimmune.com

    Historical Stock Splits

    If you bought 15,000 shares of ALT before July 25, 2007, you'd have 1 share today.
    Execution DateSplit Amount
    September 14, 20181-for-30 (Reverse Split)
    May 4, 20171-for-10 (Reverse Split)
    July 25, 20071-for-50 (Reverse Split)

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities, Continuing$266,000
    Net Cash Flow From Investing Activities, Continuing$1.20 Million
    Net Cash Flow From Financing Activities$266,000
    Net Cash Flow From Investing Activities$1.20 Million
    Net Cash Flow From Operating Activities$-27.12 Million
    Net Cash Flow, Continuing$-25.65 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Diluted Average Shares$71.08 Million
    Income/Loss From Continuing Operations Before Tax$5,000
    Research and Development$19.80 Million
    Net Income/Loss Available To Common Stockholders, Basic$-22.84 Million
    Preferred Stock Dividends And Other Adjustments$0
    Net Income/Loss Attributable To Parent$-22.84 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$-22.50 Million
    Comprehensive Income/Loss Attributable To Parent$-22.50 Million
    Comprehensive Income/Loss$-22.50 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Noncurrent Assets$2.10 Million
    Noncurrent Liabilities$5.85 Million
    Equity Attributable To Noncontrolling Interest$0
    Equity Attributable To Parent$133.38 Million
    Other Non-current Assets$1.66 Million
    Current Assets$145.76 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALT from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.